Auna S.A. (AUNA) Earnings Call Transcript
November 21, 2025
Earnings Call Speaker Segments
Thanks, operator. Hello everyone, and welcome to Auna's call to go over what we did in the third quarter. Just so you know, we have a webcast presentation that goes along with what we'll be discussing today. If you'd like a copy, it's available on our Investor Relations website, or you can reach out to Auna's Investor Relations team. Keep in mind that whenever we talk about variances, we'll be comparing them year over year, and for Mexico and Colombia we'll use FX-neutral, or local currency, figures, unless we say otherwise. Let's turn to Slide 2. Along with presenting unaudited financial results that follow International Financial Reporting Standards, we'll also cover some non-IFRS financial measures and operating metrics, among them foreign exchange neutral calculations. Before we go further, I'd ask our investors to review closely how those measures and metrics are defined in the earnings press release we issued yesterday, so they have a clear grasp of what each one means. Non-IFRS financial measures and operating metrics shouldn't be looked at on their own, nor treated as a replacement for, or something better than, IFRS financial measures — we offer them purely as supplementary information. Also, before our remarks get underway, keep in mind that some of what gets said in today's discussion could amount to forward-looking statements. Those rest on what management currently expects and believes, and they carry various risks and uncertainties that might make actual results come out materially different, including circumstances that may lie outside the company's control. These items cover a range of matters, such as the leverage ratio we are aiming for, how and when the problems involving physicians, suppliers and information systems in Mexico are expected to be settled, what the key initiatives we are carrying out in Mexico will produce, what capacity and market Torre Trecca will have after construction is finished, how our strategic plan will be executed, including getting our growth levels back and introducing the AunaWay in Mexico, the work we are doing together with Sojitz Corporation of America, the investments we intend to make in Mexico, and how additional growth and sustainable value will be created for our stakeholders. To learn about these risks, please see our Form 20-F filing with the U.S. Securities and Exchange Commission and our earnings press release. Slide 3, please. Joining us today are Suso Zamora, Executive Chairman and President; Gisele Remy, Chief Financial Officer and Executive Vice President; and Laurent Massart, Executive Vice President of Strategy and Equity Capital Markets. They'll walk through Auna's consolidated and segment financial and operating results for the third quarter, along with updates on our various strategic growth initiatives. Following that, we'll take your questions. Suso, over to you.
Thanks, Annie. Morning, everyone, and I appreciate you being on today's results call. During this quarter, what we're sharing is softer financial performance — a quarter that was essentially flat, with the main drag coming from our operations in Mexico. That said, within Mexico we can point to signs of operational activity that is both stable and expanding, plus the durability of our business model, where our operations stand in terms of development, and how resilient our owners' integrated regional platform is — all of which showed up in the robust numbers from our Peruvian and Colombian segment during the third quarter, which helped partly counter the 5% drop in total adjusted EBITDA stemming from how Mexico performed. Peru's impressive top line and EBITDA gains came from a health care pricing mix that continues to get better, strong insurance MLR, and solid expansion in plans. The risk mitigation steps we put in place in Colombia made EBITDA and cash flow stronger there. Over at our Mexico business, even with weak results, hospital operations held steady across the quarter, and we recorded a second straight quarter of increased surgery volumes, along with more oncology and cardiology services; even so, the quarter was defined by a slower-than-anticipated rebound in legacy doctors volumes and by an impact tied to rolling out new hospital information and ERP systems at Doctors Hospital; the important inroads we're making are putting Auna in position to seize the many long-term growth opportunities we identify in Mexico. We expect 2026 to bring a full recovery in Mexico, and with the New Mexico team now in place, our medium-term view stays very bullish. Even with adjusted EBITDA lower, leverage at Auna didn't change, since we carried less gross debt when the quarter ended. On top of that, our debt profile got considerably better through the refinancing we completed successfully earlier this month. Adjusted net income came in at a solid PEN 58 million for the quarter; let's now move to Slide 5. Peru and Colombia together produced the 1% rise in FX-neutral consolidated revenue. Their top lines in local currency were up 9% and 4%, respectively, partly offset by a 12% decrease in Mexico. Capacity utilization, which you'll see in the bottom left of the slide, fell 3 percentage points to 64%, the same as in the second quarter; looking year over year, a 1.5 percentage point gain in Peru's total capacity utilization was more than offset by a 5.2 percentage point drop in Colombia and a 4.4 percentage point drop in Mexico. Whereas the weaker utilization in Mexico reflected a year-over-year fall in surgery volumes and emergency visits, the decline in Colombia came about because of the risk mitigation measures we implemented there earlier in the year, which included proactively managing contracted services with government-intervened payers, while the decline in Peru resulted from adding beds to the operating capacity. Last, I want to point out that total operating capacity utilization in Mexico edged up modestly compared with the prior quarter. Planned memberships at OncoSalud rose 8%, and its MLR dropped further, to 49.3%. Let's now look more closely at the segment results, starting with Mexico on Slide 7. Naturally, Mexico had a number of positive developments this quarter. To start, as I mentioned earlier, surgical case counts rose for a second straight quarter. Next, our oncology and cardiology offerings — core pillars of the growth plan we are pursuing over the long term — were up 48% compared with the second quarter of 2025, making up 15% of revenues in Mexico. I want to stress this point. A key piece of what we do in Mexico in terms of high complexity is expanding. And on a related note, third, revenue generated by Opción Oncología’ climbed 21% from the prior quarter too. This is precisely where Auna plays a major role in reshaping health care in Mexico; this is precisely where we deliver results for patients, payers and physicians. Holding back revenue this quarter was a softer market. Another drag on our revenue was a rebound in volumes that came in below what we expected, which was affected by the physician supplier relationships that have held back how quickly the AunaWay model is being put in place in this market; it is worth noting that we have faced comparable obstacles while transforming the health care markets in Peru and Columbia. A further element was unforeseen difficulties in moving Doctors Hospital onto new information and ERP systems, which hurt billings. Putting these systems in place forms part of a wider multiyear IT transition aimed at aligning technology throughout Auna's businesses and geographies, and at raising the standard of the data and information we rely on to run Auna and to care for patients. Reduced revenues weighed on Mexico's gross profit and, as a result, adjusted EBITDA, and additional elements played a role, among them a larger share of lower-margin services tied to service contracts for state employees at our OCA facility. Even so, the margin came in at 29% for the third quarter. Before I turn to how our other business segments performed, I want to provide an update on the main growth initiatives we currently have under way in Mexico, which appear on Slide 8. So bringing in, keeping and putting resources behind talent is a core part of our growth plan in Mexico. The supply of health care talent in the Monterrey marketplace is limited. That said, we have overhauled the leadership team in Mexico. Alejandro Torres is in charge of our Monterrey health care operations. In the past, he occupied senior positions at Star Médica and TecSalud. We also brought on a new Chief Medical Officer, a highly regarded and very credible physician in Monterrey, who is making a substantial and favorable difference as we work with physicians to build our practices and enhance medical resolution for our patients. We have brought on a new Head of Commercial Operations who starts with the company this week, along with other senior leaders for our Mexican hospitals. Each of them brings Auna considerable, combined and complementary expertise in Mexico's health care market, plus decades of experience in Monterrey. We are introducing a set of package service offerings and deepening our collaboration with leading physicians so we can further penetrate 3 important market segments; this, of course, will broaden revenue streams and lift capacity utilization at our health care facilities. The first area is Out-of-Pocket, a profitable segment that right now accounts for just 8% of what we bring in across Mexico, and our goal is to grow that to 20% by the close of next year. During Q3, we grew this segment by 15%. When it comes to Corporate, we keep building appealing, cost-effective offerings so we can provide extra services to the workforces of our corporate customers. Government agencies are another appealing area. So we're looking into customized services for employees of the municipalities that operate Monterrey, plus those working for government bodies located inside it. Getting physicians involved and boosting their productivity are likewise central to our approach in Mexico, and that means bringing in the finest doctors and nurses for high complexity management; it also involves a set of quality and productivity efforts that keep building momentum. By focusing on merely 140 of our leading physicians, who account for roughly 25% to 35% of revenues at every one of our hospitals, we have strengthened our ties with them, and with payers and suppliers too. This straightforward step has upgraded medical practices, lifted operating performance, made costs more predictable and, naturally, improved control. During the previous month, 50% of those physicians saw productivity climb by double digits compared with the month before. Also, that same month, we managed to bring on board a team of 10 physicians from a rival local hospital.
When it comes to payers, our goal is to broaden Auna's involvement with preferred provider networks belonging to several of Mexico's biggest insurance companies. So starting in 2026, our health care facilities expect to handle greater patient access along with higher service volumes, which will drive capacity utilization upward. Another essential piece of our Mexico growth plan involves scaling up and strengthening Auna's oncology capabilities. At the close of October, we held Auna's Second Oncology Congress in Monterrey, bringing together over 70 oncologists from throughout Mexico; that occasion also served to formally open a new OncoCenter at our Doctors Hospital. It will function as a center of excellence, delivering oncology services from one location and elevating patient care and experience, all while being integrated with Auna's regional health care network. The work we've put into oncology is already delivering results, and this new center ought to substantially boost our activity in Monterrey; once again, this reflects the implementation of the AunaWay, which will give Auna the differentiating aspects needed to sustain our high growth ambitions in high complexity. Finally, this slide shows the rollout of a new comprehensive IT system for our Mexico operations, bringing them up to our standards. Among its many benefits, it will strengthen the integration of financial and operational data, sharpen management visibility throughout the businesses, assist us in controlling costs more effectively and improve decision-making at our health care facilities. Let's turn to Slide 9 to talk about Peru's third quarter performance. Our Peru business, Auna's scalable, integrated, best practice health care platform, showed the strength and predictability of our model when it operates at scale. As it deepened its penetration of the country's health care market and grew its business with third-party payers, health care revenues rose 9%, driven mainly by higher ticket and greater volume of emergency visits and ambulatory care. OncoSalud, the health plans business, saw revenues climb 8%, chiefly because of increased membership and annual price adjustments. We keep seeing considerable opportunity ahead, and Peru will stay a key contributor to Auna's growth. Peru's adjusted EBITDA rose 15%, with a margin that increased 1.1 percentage points to 22.7%; driving that EBITDA growth were greater efficiencies in surgical procedures and better pharmaceutical costs at OncoSalud, which helped produce its low MLR. Now to Colombia on Slide 10. Colombia's top line expanded 5%, largely as a result of implementing risk-sharing models such as prospective global payments, which are unique, since they're difficult to replicate, generate stable margins and high occupancy and yield a reliable and positive cash cycle. These accounted for 18% of Colombia's revenue, up from 14% in the third quarter of 2024. Additionally, by the end of the third quarter, the portion of revenues from Nueva EPS, one of the major government-intervened payers in Colombia, declined from 20% in last year's quarter to 13%. Also, we brought on Salud Total as a payer through a new PGP program, which shows how well our push to broaden the mix of payers Auna works with in that country has gone. Even though surgical volumes came in lower because we restricted services to intervention payers, bigger average tickets for surgery plus growth in chemotherapy and imaging services did more than make up for that drop and helped drive revenue growth for the quarter. That growth produced an 18% rise in Colombia's adjusted EBITDA and a margin improvement of 1.7 percentage points, along with smaller impairment losses during the quarter, partly offset by higher doctor remuneration. That wraps up my review of the quarter. I'll now hand things over to Gisele for her portion of today's presentation.
Thanks, Suso. Turning to Slide 12, we lay out how much revenue comes from each geographic piece of Auna's diversified regional platform. The bar charts show that Peru was still responsible for much more than half of what our platform brought in for the third quarter and year-to-date; and since its top line rose 9% in the quarter, Peru keeps serving as a solid, dependable engine of growth and cash flow. Colombia, even with the risk mitigation steps we took to keep a healthy cap cycle, likewise added to revenue growth, posting 4% growth in local currency for the quarter. Turning to Mexico, we should reiterate that the 12% drop in revenue came about because volumes are still recovering slowly, the market has been sluggish, and there were also nonoperating effects, including the multisystem migration. And finally, as Suso said, we expect revenue in Mexico to return to growth in the coming year. Now let's turn to Slide 13. Peru likewise delivered a sizable contribution to adjusted EBITDA growth, posting an increase of 15%. Its margin in the quarter was also solid, at 22.7%. Although we chose to put cash preservation ahead of growth, Colombia too bolstered our profitability and widened its margin compared with the same quarter a year earlier, which reflected higher revenues and reduced provisions. The 5% drop in our consolidated adjusted EBITDA on an FX-neutral basis came from Mexico, driven by a substantial decline in revenue along with the payer and service mix we saw this quarter. Looking ahead to 2026, we anticipate EBITDA growth as we move forward with rolling out our business model, as our various growth initiatives steadily build momentum, and as we apply what we learned from the systems implementation at Doctors Hospital to the next round of migrations. Turning to Slide 14, we lay out the year-over-year bridge for adjusted net income, with Mexico's effect on operating income standing out as the largest factor. Two things partly made up for that, as shown in the center of the bridge: an extra PEN 11 million in finance income tied to FX, plus a PEN 21 million, or 16%, drop in interest expenses. On top of that, non-cash and extraordinary items fell by PEN 31 million, and those figures reflect a favorable effect in 2025 stemming from the OCA holdback obligations that arose in the third quarter of 2024. Turning now to the cash flow bridge on Slide #15: across the 9-month period, pretax operating cash flow came in at PEN 595 million, down 5%, driven largely by weaker revenues in Mexico and receivables collection setbacks linked to the systems integration being carried out there. One more thing that played a role: we paid performance bonuses to physicians at Opción Oncología related to their move over to Auna. Our pretax operating cash flow came in 65% higher than the second quarter of this year on a sequential basis, helped by better collections and cash conversion in Colombia. Since Auna ranks as a leading health care provider in that country, intervene payers tend to treat us as a priority when it comes to money they owe, and collections have stayed healthy. That said, how things stand with the intervene payers can shift quickly, so we're keeping a close watch. Toward the middle of that bridge, you'll see PEN 119 million listed as investments. That figure sits 31% beneath where we were across the opening 9 months of 2024. Breaking that down, it was mostly PEN 98 million of CapEx, plus PEN 21 million tied to amortized payments on the OCA holdback obligations — those wrapped up during the second quarter — along with the IMAT Oncomedica earnout, where the remaining outstanding balance stands at just PEN 12 million right now. Continuing along the bridge, financing consumed PEN 336 million of cash, a figure 3% under the comparable 9-month stretch a year ago. Breaking down that overall figure, term loan repayments account for PEN 163 million. Hedge premium and swap interest payments take up PEN 26 million. Interest on our 2029 notes comes to PEN 58 million. Interest on our working capital facilities adds PEN 50 million. And finally, borrowed working capital amounts to PEN 39 million. That brings us to where our cash stood at quarter's end: a solid PEN 226 million, which is nevertheless 4.2% lower than the level we began the year at. Let me now share a few points about our debt, starting on Slide #16. Our debt structure is still in good shape, and we remain dedicated to reducing our leverage to 3x net debt to EBITDA over the medium term. When it came to handling Auna's debt, we took advantage of what was happening in the credit markets, along with continued demand from both bond buyers and lending institutions. That combination allowed us to complete the $765 million refinancing package we had previously announced to the market earlier this month. As part of that deal, we successfully issued $365 million in senior secured notes. We also finalized a term loan worth $400 million equivalent, issued in Mexican pesos. This matches up with the Mexican exposure in Auna's operations. The loan also includes a provision for an additional $60 million equivalent tranche in Peruvian soles, which is expected to be disbursed very soon. The U.S. dollar bond and the Mexican peso term loan together deliver 125 basis points in savings relative to the interest rates under the previous debt structure; we're also quite pleased to have brought new lenders into the debt structure, among them the IFC, which participated in the Mexican peso term loan and additionally anchored 10% of the bond offering. All told, beyond extending our maturities, lowering financing costs and boosting short-term liquidity, this refinancing hands us greater financial flexibility to keep investing in our medium- to long-term growth initiatives. On those grounds, the rating agencies assigned a B+ rating to the 2032 notes and view the transaction as credit positive; that wraps up my review of the results. Before we open things up for your questions, Suso wants to give a wrap-up on the quarter.
Appreciate that, Gisele. To wrap up today's presentation, I'd like to give you a rundown of where our strategy and priorities stand as we head toward the close of 2025 and look at 2026. Our third quarter shows how Auna's broad footprint and integrated approach deliver lasting resilience. Peru captures what Auna's scalable, integrated, best-practice health care platform looks like, and it shows how strong and predictable our model becomes when run at scale. Peru keeps driving meaningful contributions to Auna's near- and midterm growth, powered by an improving MLR, steady profitability, and our proven vertically integrated model operating at scale. Right now, the main lever we're pulling is additional growth in the mid-segment market, along with risk sharing alongside private and public payers. Within Peru, the recent Trecca milestone underscores just how confident people are in the country's health care future and spotlights the long-term opportunity we still see there. Peru remains a formidable growth market for Auna as we extend our capabilities into a market where private insurance penetration sits at just 6% and where we expect to capture a sizable share of the next wave of partially insured and uninsured people in the country. Over in Colombia, measured growth keeps fueling the business, and our risk mitigation strategy has genuinely delivered. Even with tough externalities, results came in very strong this quarter, since Auna successfully diversified away from intervene payers and, over the past year, prioritized dependable cash flows from PGPs. Colombia stays a key market for us and a major contributor to scale and medical best practices throughout the region. As I've been trying to convey, our focus is on Mexico. We've got a terrific, new, deeply experienced group of local leaders who are eager about what's possible in Monterrey and across the country, and they're driving the effort to reignite growth. We've made genuine progress, posting a second consecutive quarter of volume recovery in surgeries plus stellar 48% growth in oncology and cardiology services. It's also worth flagging our recent public announcement about partnering with Sojitz. That lets us speed up growth in Mexico beyond what we could accomplish alone, all while staying on our disciplined deleveraging path and holding to our target of pushing leverage under 3x. Last, we stay sharply focused on our fellow investors and shareholders. After completing our debt refinancing successfully this quarter, we've already taken a major step toward strengthening the capital structure and lowering long-term financial risk. For the rest of the year, we'll keep evaluating every option to support and enhance shareholder value, since we firmly believe Auna's current share price fails to reflect the intrinsic value of our integrated platform and its long-term potential in the Latin American health care market; we're excited about what we can deliver in 2026. Thanks for your time, and we're now ready to take your questions.
Two things I'd like to ask, with a bit more focus on where you're headed strategically. First, regarding your Mexico plans and that MoU you made public with Sojitz: can you lay out the thinking behind moving into Mexico this quickly, and how does this new agenda fit with your objective of bringing down Auna's leverage while scaling up Mexican operations? Then my second one concerns Colombia. Could a possible shift in that country's leadership relieve some of the pressure on EPS? Or is there something more deeply structural holding back any real improvement across the coming years?
Thanks, Mauricio. Starting with Mexico — as we've consistently framed it, Auna represents a growth story, and despite what 2025 showed, there's a genuinely attractive chance to grow in Mexico, essentially replicating what we've achieved in other markets. Since our insurance products have established particular service offerings across various cities — Guadalajara, Tijuana, <<inaudible>>, plus Mexico City — a number of those open up future investment possibilities. Right now, I want to state this plainly: leverage sits as a central worry for us, and our aim is to get it under 3x. That means we lack a balance sheet capable of deploying capital. At present, the share price is quite beaten down, which also constrained us when it came to share issuance. That's how we identified a truly compelling chance with Sojitz. Our work alongside Sojitz — a wonderful and respected firm, with impressive leadership — has been ongoing. Over the past 5 years, we've been in discussions with Sojitz, evaluating various ways to work together. The MoU we hammered out over recent months cements our partnership and establishes a structure for joint investment in Mexico. So investors should go read the press release from a few months back detailing our Mexico intentions under this Sojitz MoU. It's an MoU aimed at speeding up Auna's expansion in Mexico. Sojitz makes an excellent partner, and we're thrilled that, together, we can accomplish more. Once again, this is something that lets us seize the Mexican opportunity while keeping our leverage target intact. That matters greatly to us. Turning to EPS in Colombia: my view is that the political climate there, especially with elections coming, won't shift anything within the next 6 months. I'm not particularly hopeful about the whole of 2026 either, yet I believe the sector is under enough strain that the government will have to act; and I notice certain milestones that carry weight. <<inaudible>> — the insurance intervenor, the EPS insurance payer — was recently recapitalized by the central government, which restores it as a creditworthy entity. So I do anticipate specific measures that will prove essential for restoring stability to Colombia's health care sector. However, given the lateral year, I notice there may be a postponement regarding that, possibly until the latter half of next year, and in all likelihood the year following; yet once more, our standing as a favored supplier of highly complex offerings to the majority of insurers in Colombia gives us quicker remittances, favorable profitability, and substantial volumes. That has been proven during Colombia's toughest periods; therefore I hold no pessimism whatsoever about the appealing returns and expansion that Auna's positioning will generate amid a very challenging Colombian landscape. I'd like to emphasize that our Colombian activities keep expanding, despite what is happening in Colombia. It's a real privilege to hold this positioning, along with the confidence of numerous patients and numerous payers. And we remain enthusiastic about Colombia, despite the unpredictability within the political climate. Thank you, Mauricio. Should I have left anything out, Gisele, kindly fill in the gaps if necessary.
Absolutely, Mauricio — to build on what was said regarding the second half of the Colombia question, I'd like to add that, as Suso noted, our outlook on Colombia stays quite positive. It's a core piece of the Auna platform, as you're aware. Even with the external pressures in the picture, we've handled things well. We take a constructive view that certain political disturbances are affecting payment flows, and our belief is that as we approach the close of next year and move into 2027, there should be particular openings for catalysts within the operation. Also, to expand on what Suso raised and make things clear, as we've stated before, we've cut our exposure to <<inaudible>> substantially across the last year, bringing it down from 20% to 13% of Colombian revenues. More recently — we've also taken note of the announcement, the shared stakeholdership involving the government and <<inaudible>>, and in our view the government holding a direct stake in this payer is a favorable signal.
And Gisele, I'd like to add to what I said earlier, Mauricio. Once again, Auna possesses a highly appealing pipeline in Mexico, thanks to Sojitz, along with a constrained balance sheet at present and the current share price. We need to ensure we're still able to move forward on that pipeline as part of our Sojitz partnership. That piece is essential to what I just said, Mauricio.
Right. But as a quick follow-up, might this fall under Sojitz's interest in putting money into Auna as such and shoring up the capital structure, or does it only concern fresh opportunities?
Well, I'd rather not claim to represent Sojitz, though the conversations we've held over the years are quite plain. Our integrated model appeals to them. Auna appeals to them. Earlier on, we talked about matters in Peru. The insurance operation tied into the health care arm appeals to them. So I won't — the MoU leaves a broad scope for talking over various things, yet in my view it isn't confined to new items; it's confined to ensuring we can advance Auna's growth prospects, above all in Mexico, and I'd say across all of Auna too.
Appreciate it, operator. Now, on the questions—we're likely going to hear some of them more than once, so if there's anything we don't get to, just flag it for us, though we'll be handling it on our end. Up first from the webcast, Joseph Giordano with JPMorgan asks: could you share additional specifics regarding the Sojitz partnership and the Trecca project? What progress has been made in Mexico during Q4 '25? And at what point should operations return to 2024 levels when it comes to operating leverage?
Alright, I’ll cover part of it, and Gisele, if I leave anything out, please jump in. So regarding Trecca — and I think on Sojitz we’ve discussed quite a bit — we want to make sure the market stays informed as that MoU moves forward. Now, Trecca is a public-private partnership that was awarded to Auna back in 2010. These are among the hidden opportunities inside Auna; we’ve been working with Salud, which is Social Security Peru, and PROINVERSIÓN, the investment promotion agency there, to modify the concession and secure all the permits needed to launch the project. What we’ve shared is that the building permit has been authorized, and that was a major obstacle over the past couple of years. Let me sum up: this is a very compelling project. When you look at health care globally, you see it of course in a limited way, but in Latin America, for us, there will be a sizable total addressable market of private payers. And then there’s a large segment of payers that are either indirectly or directly state-owned; so this is a contract, an 18-year contract with a 2-year construction period. We’ll begin building mostly at the start of next year; it will take us 2 years, and after that we have 18 years. Across those 18 years, we’re talking about 1.9 million ambulatory services, 0.5 million prevention package services, and others that add up to 3.2 million services annually. This is a major undertaking to serve social security beneficiaries in Peru. When it scales, this contract will certainly deliver sales of more than $200 million a year. It’s a very compelling opportunity as we expand our footprint, not only within our total addressable market in the private sector, but also indirectly with the state-served sector; so I’m really enthusiastic about Trecca. It’s not just about Peru; these are the kinds of conversations we’re having with government authorities in Mexico as well. So it’s really interesting to prove our capabilities to deliver services to millions. And I think that’s what we’re going to demonstrate we can do over the next couple of years when it comes to Trecca. Gisele...
Absolutely. And I'd add to that, Suso, regarding Trecca and how public-private partnerships get set up in Peru — the structure can be arranged so that it ends up being debt-neutral for Auna.
That matters a great deal. Thanks, Gisele. This deal, along with the pipeline in Mexico, is debt-neutral to debt reduction for Auna — extremely important. We will keep expanding without putting any extra debt onto our balance sheet. These public-private partnerships in Peru follow a very defined process, since the state funds not just the construction but all the services as well; so there will be no effect on leverage for Auna. I believe there were a few other questions from Joe, Gisele.
Right, and during that we went over the announcement about the subject, plus how things are going for us in Mexico.
Perfect. I did — so I believe Joe raised a point as well regarding if we'll return to where we were in 2024 when it comes to operating leverage. And I'm aware we don't like to provide many figures — projections or guidance. 2025 is going to be a level year. 2026 is going to be a year of growth. And without a doubt, Mexico will see a year of growth.
Appreciate that, Suso. Given how many questions are coming in at the moment, I'll keep going with them. Our next one is from <<inaudible>>. Regarding the turnaround and the inflection everyone expects, we recognize that the strategy for turning things around is already underway, but which key KPIs ought we to be monitoring to verify a real recovery in 2026? Occupancy, payer mix, and surgical productivity are examples. At what point do you anticipate significant gains in revenues and EBITDA? There's an additional question about the recent softness in the share price. Despite operations in Peru and Colombia holding up well, the share has lagged. Can you tell whether a particular institutional investor has been selling out? Are you talking with any of those holders in order to shore up the investment case? And then just 1 more. I need to read the third one, though we've likely already addressed it. About the Sojitz opportunity, might you offer further specifics on the following steps with Sojitz Mexico? Do you perceive any chances for co-investment in new assets, or possibly partial assets, with asset sales, to speed up returns on capital?
Okay, I believe I'll go ahead and start. On the share price query. To begin with, we feel strongly that today's valuations already capture what the business is fundamentally worth. Nothing meaningful has shifted relative to the fundamentals we've been communicating. Naturally, we constantly review options aimed at propping up and boosting value for our shareholders, and we'll pass those along to all of you as things develop, and these matters will be taken up with the Board in the very near future. Let's engage in some speculation, since earlier this year public filings revealed that a rival of ours in Mexico submitted a request to Mexico's antitrust regulator seeking to acquire additional Auna shares. Based on recent public SEC filings, it's apparent that this top-tier Mexican healthcare company has been offloading stock steadily over the last month, which leads us to believe those requests went nowhere. That said, we cannot know for sure. There isn't — much of this information remains public, aside from what's been disclosed to the SEC. And we've observed unusually heavy volumes relative to historical levels that line up with these antitrust developments. So that's just our guess; we are, obviously — the latest filings became public seven days ago, and we're working to reach out to whoever is doing the selling to see whether we might suggest some block trades that wouldn't hurt the share price the way it's already been hurt. Once more, I want to stress that nothing about the company's fundamentals has shifted across the past 45 days, during which the stock fell — I believe, I'm not sure of the figure, somewhere around 25% or 30%. Nothing at Auna has changed that would cause that.
Thanks, Suso. Now we’ll move on to the following question, which is from <<inaudible>> at Deutsche Bank. Could you share your thoughts on the timeline for return on investment regarding Mexico’s performance, as well as provide some commentary on how the share price has performed?
Regarding the stock price, I believe that's been addressed. Gisele, would you like to discuss return on investment?
Absolutely, happy to address that. I'd say the key point here is that at Auna, when we look at both our investments and our operations, we assess everything through the lens of return on invested capital. That's exactly why we're always searching for opportunities to improve those returns — by getting more out of our assets and by lowering how much capital we have tied up. When it comes to the Mexico investment timeline specifically, as was said earlier on this call, this year has brought some setbacks, driven by the factors that have already been covered. That said, for Mexico we do anticipate 2026 will be a year of growth.
Thanks, Gisele. Our following question is from <<inaudible>> at Fundamental Capital. On the topic of growth initiatives, do you intend to put in additional beds in Peru? Then for Mexico, regarding that 500 million in expansion plans, what number of beds do you anticipate adding in that market?
We won't provide any forecast regarding how much capacity will expand. Still, the general trajectory is that Auna will be adding capacity — beds, yes, but also chemotherapy, radiotherapy, and surgery rooms, all of which naturally help fill our beds in Peru specifically. There's some expansion there. Certain plans we have would largely open in 2027 rather than 2026. We also expect to put money into nations or municipalities where our hospital presence is already substantial, with a greater emphasis on ambulatory care, since fields like oncology, orthopedics, and cardiology in particular are shifting toward outpatient settings. As for Mexico, we intend to replicate our approach of urban health care ecosystems combined with high complexity, which demands beds — a minimum of between 75 and 150 beds established in every city to create that urban health care ecosystem.
Thanks, Suso. Our following question is from <<inaudible>>, and then one more comes in from <<inaudible>> SG Analytics. Since both are quite alike and deal with the same subject, I'll combine them. They concern the Sojitz partnership. Can you make clear if this tie-up is meant to fit within the $500 million Mexico investment plan announced earlier, spread across the next 3 to 5 years? Or does it stand as its own separate effort? Also, how should we view Sojitz's part when it comes to co-investment, capital contributions, or taking part in carrying out the pipeline? Do you have — might you shed light on what the character of that $500 million investment actually is? And are there any impacts on the top line that can be quantified? Thank you.
I believe I've covered this — I also believe I've shown that indeed, that $500 million ties back to our MoU with Sojitz. So the chance here is a 5-year, $500 million opportunity. And as for what we've signed with Sojitz under the MoU, no specific figure is attached to it, yet it makes up a sizable portion of what we plan to invest in Mexico. Naturally, this partnership is going to drive considerable top line growth, and in the past we've witnessed that reflected in our EBITDA growth as well. And naturally, the aim behind all of these investments is to keep growing our top line at high-teens and above. Is there anything I'm leaving out, Gisele or Annie?
I believe that's fine. I'll go ahead and read the following one, unless Gisele would like to add something.
No, I think we're good.
Okay.
All right. Then the following question is from <<inaudible>> at Deutsche Bank. Could you share your thoughts on Auna's insurance risk management policy as it applies across the entire group?
Thanks. That's an excellent inquiry. The response is complicated, yet we handled risk to a large degree regarding MLR according to the category of policy; take oncology as an illustration. Thus, the fundamental oncology exposure in our insurance program is managed using a 50% MLR. Pursuing that target generates two separate courses of action. The first is pricing, while the second involves containing costs. Containing costs will be carried out by ensuring physicians comply with our protocols, by our acquiring the most efficacious medications, equipment, and therapeutic treatments, which, when done at scale, are hard for competitors to copy. And that yields, reliably, that 60%. With the small number of policies we hold in Peru and for general healthcare, we're doing the same, and those also have quite appealing MLRs in which we're limiting the fundamental risk. So through this capacity to oversee all these plans on an ongoing basis; we reprice on an ongoing basis, and we limit costs and spot items that inch upward and how we — and we restrain them continually each month across various practices, with physicians engaging in much of the conversation about why a particular service shouldn't be included, why a particular medication shouldn't be included, since we're constantly focused on scale within the plans and on what we provide to plan members.
Thanks, Suso. So we’ve reached the final question submitted online. It’s from <<inaudible>> at HSBC. As I remember it, during last year there was discussion about a preferred payer network as well as a bundled package aimed at corporates in Mexico. Have those now been introduced, or should these efforts be understood as separate? And what’s your approach for raising the out-of-pocket sales mix in Mexico?
Good, so the preferred payer network is now live, though conversations with payers keep going; we're quite thrilled and really keen, and we feel that with this — these matters get negotiated, we sit down with them annually, so that process is happening right now; and my sense is we'll see genuinely favorable outcomes over the next few weeks when it comes to landing in the top-tier preferred networks of Mexico's biggest insurers for what we run in Monterrey. So this work carries on. It isn't the kind of thing that wraps up in — once more it comes down to containing costs and the way we now engage payers. On the out-of-pocket sales mix, that's an area where, in my view, we've pursued it in Monterrey with limited ambition; and we are certainly changing that. As I noted in the press release, I believe. Our goal is to double penetration of sales — push penetration of sales among out-of-pocket patients beyond double. Two main things get us there. Plenty of bundled offerings from attorney for particular preventive procedures like colonoscopies and even surgical cases, orthopedic surgeries too; we bundle services in an integrated fashion spanning diagnosis through to post-surgery, done aggressively with solid margin, yet aggressively relative to what a patient encounters at other hospitals; and second, we introduced, I believe, around midyear, we rolled out a very — it's a very swift-turnaround answer for out-of-pocket patients who walk in seeking a quote for particular services. And what we're aiming for is to capture every inquiry that arrives at the hospital and never let it slip away. So our pricing for out-of-pocket patients is highly aggressive. I have to stress that the out-of-pocket segment carries very strong margins. That leaves plenty of room to be highly aggressive there. So we've rolled out an internal process that's extremely nimble, one that moves with urgency to reply and to secure the out-of-pocket patient who walks in.
Maybe I could jump in here, Suso, and provide a bit more clarity regarding what <<inaudible>> asked. The six initiatives Suso laid out today are quite significant and very specific, and they're things we're pursuing within our Mexican operation. A number of them are fresh, while others have already been launched but keep maturing and developing further. These efforts are tangible, and they're what will carry us back to growth in 2026.
Gisele, thanks. And Suso, I appreciate your responses. I'm not seeing any further questions come in. So with that, I'll hand things back over to Suso so he can wrap up.
Appreciate it, Annie, and much gratitude to the entire Auna crew, plus every shareholder and investor who tracks us, along with the analysts in the research community covering us too; indeed, it has been a tough 12 months. Many initiatives have been undertaken. A portion of these can be disclosed to public investors, while others are still in the middle of being rolled out. Mexico. Without question, Mexico is going to become an enormous growth market for Auna; we're genuinely thrilled about what we can offer. We're seeing proof of engagement with numerous counterparties regarding this. Sojitz and the interest they've shown in Mexico stands as evidence of our efforts and the scale of the opportunity; so yes, a hard year. An extremely promising future lies ahead for Auna in Mexico and across the rest of the region, no question. I'd also like to point out that at times we portray Peru as a mature market; we hold the dominant position there, yet it isn't a mature market. Trecca shows how Auna can achieve a substantial boost; it isn't even charted anywhere how we keep capturing more and more market share from — not from the traditional established players, but rather from the state and from out-of-pocket spending. Colombia is expanding, despite the challenges in Columbia. I don't wish to downplay Colombia's difficulties. We're expanding. We're expanding profitably, even more profitably, and we're collecting well in a highly stressed market. That's what Auna is capable of. And Sojitz, Trecca — all of these are hidden gems in our possession that will deliver significant growth results down the road. We will certainly take action regarding the share price. We won't simply sit by without doing something about it, and we'll be talking that over at the Board level at the appropriate moment too. Many thanks for your support. Many thanks for your coverage. And with that, I'd like to wrap up the earnings release call and its Q&A portion. Thank you so much.
This concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Auna S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Auna S.A. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.